First Launch Insights for Emerging Pharma Companies in the US
Drawing on over a decade of U.S. data, this analysis explores how emerging pharma companies approach their first product launches. Key findings show the vast majority commercialize independently, with more than half targeting rare diseases. Advanced modalities now represent a growing share of all first launches. For more info: https://www.zs.com/insights/us....-biotech-and-pharma-